7,685 Shares in Halozyme Therapeutics, Inc. $HALO Bought by Whalen Wealth Management Inc.

Whalen Wealth Management Inc. purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 7,685 shares of the biopharmaceutical company’s stock, valued at approximately $602,000.

Several other institutional investors have also bought and sold shares of the business. Empowered Funds LLC purchased a new position in shares of Halozyme Therapeutics in the 1st quarter worth $755,000. Acadian Asset Management LLC bought a new position in shares of Halozyme Therapeutics in the 1st quarter valued at about $195,000. Hsbc Holdings PLC lifted its holdings in shares of Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. grew its position in Halozyme Therapeutics by 6.2% in the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 650 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on HALO shares. UBS Group restated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. HC Wainwright boosted their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Citizens Jmp increased their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a report on Friday, August 7th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, Wells Fargo & Company lifted their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $79,987,320.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 64,103 shares of company stock valued at $5,226,496. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $108.64 on Tuesday. The stock has a 50 day moving average price of $83.94 and a 200 day moving average price of $73.96. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $109.10. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The firm has a market capitalization of $12.33 billion, a P/E ratio of 32.43, a P/E/G ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the company posted $1.54 EPS. Halozyme Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.